TruScreen Continues Strong Sales Growth in Q3 FY2024

NZX/ASX Announcement

25 January 2024

TruScreen Continues Strong Sales Growth in Q3 FY2024

Highlights

• Revenues YTD to 31 December 2023 USD $887,958.00 (NZD$1,465,131), a 34 % increase
on prior year
• SUS unit sales exceeded total of last financial year, reaching 141,300 by 31 December
2023 (9 months)
• China continuing to be major contributor
• Zimbabwe tender won and invoiced for 10,800 SUS

Truscreen Group Limited (NZX/ASX: TRU) is pleased to report a 40% growth in sales of devices and
a 22% growth in sales of Single Disposable Sensor (SUS) for the nine months to 31 December 2023,
over the same period prior year.
The major contributor to this growth is China following recognition/endorsement of TruScreen in the
major national Guidelines, by the Chinese Society of Colposcopy and Cervical Pathology (CSCCP),
published in the July 2023 edition of CSCCP's journal and the recommendation in the prestigious
Blue Book in China. A roadshow by the Company’s distributor, Siweixiangtai Tech Co. Ltd (SWXT),
has generatedsupported this growth, resulting in installation of TruScreen technology in several new
major hospitals.
The successful Zimbabwe screening program under the National Aids Council has screened a total
of 14,000 women in Masvingo province to date. The program continues with planned TruScreen
Ministry of Health evaluation in the coming months, and it is anticipated that the program will be
expanded beyond Masvingo province in financial year 2025.

The CEO, Dr Beata Edling commented:
“I’m delighted to report on the Q3 FY2024 results. We congratulate our partner, SWXT, in achieving
strong growth in China, building on the recognition of TruScreen in the guidelines. We continue to
work closely with the National AIDS Council of Ministry of Health in Zimbabwe in advancing the
successful point-of-care program in Masvingo Province. ”

This announcement has been approved by the Board.
Ends

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com





About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special
brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is
sent to a laboratory for a pathologist to examine under a microscope. https://www.cancer.net/navigating-
cancer-care/diagnosing-cancer/tests-and-procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be
done at the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-
types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample
used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical
cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be
done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-
types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia,
please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council